Cid C, Ortega-Valín F, Valero M, Muñoz R, Pascual J
Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Santander.
Neurologia. 1999 Jun-Jul;14(6):315-8.
In this work we present our experience with a seven-day protocol of i.v. dihydroergotamine (DHE) in the treatment of 6 patients (7 treatments) suffering from intractable transformed migraine. All of them were admitted to hospital and treated for one week with a protocol which included DHE doses between 0.5-1 mg/8 h. One patient did not respond. The remaining 6 became free of pain in under 48 hours after the beginning of treatment. This positive effect remained for between 15 days and 3 months. All patients experienced adverse events; however, these were slight and ceased when the DHE dose was reduced. DHE is an effective and quick option for the short-term treatment of patients with severe transformed migraine resistant to other medications.
在本研究中,我们介绍了使用静脉注射双氢麦角胺(DHE)进行为期7天的治疗方案,治疗6例(7次治疗)顽固性转化型偏头痛患者的经验。所有患者均入院,并采用包含每8小时0.5 - 1毫克DHE剂量的方案进行了为期一周的治疗。1例患者无反应。其余6例患者在治疗开始后48小时内疼痛消失。这种积极效果持续了15天至3个月。所有患者均出现了不良事件;然而,这些不良事件较轻,在降低DHE剂量后即停止。DHE是对其他药物耐药的严重转化型偏头痛患者进行短期治疗的一种有效且快速的选择。